Skip to main content

Heidelberg Pharma AG Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma

Written by Kirsten Ruehl on . Posted in Client News.

[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]